A Conversation about Foot and Mouth Disease with Biopharma

In August 2024, by successfully registering its quadrivalent Foot and Mouth Disease (FMD) vaccine tailored for Eastern Africa, BIOPHARMA (Société de Productions Biologiques et Pharmaceutiques) qualified to become the first official “competitor” of the AgResults FMD Vaccine Challenge Project. We recently sat down with representatives from BIOPHARMA to learn more about the organization’s mission and their reasoning for participating in this Pay-for-Results prize competition.

Why did BIOPHARMA decide to participate in the AgResults FMD Vaccine Challenge Project?

Morocco has built strong partnerships with African institutions, reinforcing its regional role. Its 2017 reintegration into the African Union underscores its commitment to African cooperation. BIOPHARMA, a state-owned veterinary vaccine company, is vital for Morocco and the region, eliminating diseases like African Horse Sickness and controlling FMD with high-quality vaccines.

Supporting Morocco’s South-South cooperation, BIOPHARMA develops vaccines for diseases affecting African nations, exporting millions of doses annually. Since 2020, the AgResults FMD Vaccine Challenge Project has been central to BIOPHARMA’s R&D, aligning with Morocco’s vision of “Africa by Africans and Africans for Africa.”  

Why is tackling Foot and Mouth Disease in Eastern Africa important to BIOPHARMA?

The AgResults FMD Vaccine Challenge Project promotes innovation and strengthens East African countries’ ability to control and prevent FMD, a highly contagious disease affecting cattle, sheep, pigs, and goats. The project’s cost-sharing mechanism is economically attractive to vaccine producers, increasing production volume and revenue. It also creates new market opportunities, allowing producers to enter regions needing more vaccines and enhancing their global position. For BIOPHARMA, the project offers an opportunity to enter the East African market, providing safe and tested FMD vaccines while benefiting from reduced costly imports.

Related, what is the biggest benefit to having an effective FMD vaccine for the region?

An effective FMD vaccine offers East Africa significant benefits in economic stability, public health, and agricultural productivity.

Economically, FMD vaccination reduces financial losses from decreased livestock productivity and trade restrictions. Effective vaccines help maintain stable meat and milk production and facilitate smoother trade relations regionally and globally. Tailored vaccines play a crucial role in disease control by addressing the region’s specific epidemiological context. This enhances herd productivity and boosts the local economy while strengthening resilience against future outbreaks, ensuring better disease management.

Health-wise, widespread vaccination prevents the rapid spread of FMD, a highly contagious disease that can cross borders and threaten regional public health. Coordinated efforts help avoid outbreaks and maintain better control over animal health.

The involvement of the Pirbright Institute, a leading FMD reference laboratory, adds credibility and scientific rigor. The Pirbright Institute developed a panel of circulating FMD serotypes relevant to East Africa, ensuring vaccine effectiveness. Additionally, the project strengthens the African Union’s Pan African Veterinary Vaccine Centre (AU-PANVAC) by equipping its reference laboratory with tools and expertise to assess vaccine quality, contributing to long-term sustainability in the region’s disease management strategies.

What does BIOPHARMA see as the biggest challenge participating in the AgResults project?

Participating in the AgResults project has provided BIOPHARMA with valuable opportunities and significant challenges in meeting the required eligibility criteria, spanning technical, regulatory, and financial aspects.

Technical Challenges:

1. Developing and validating a vaccine for specific FMD strains in East Africa required extensive research and rigorous testing. Each batch had to undergo detailed controls and testing by the Pirbright Institute.
2. Logistics for controlling cattle, collecting and preserving serum samples, and ongoing serological monitoring posed significant challenges. Coordinating these tasks across different countries, ensuring proper sample handling, and maintaining consistent monitoring standards were critical.

Regulatory Challenges:

Some of the biggest regulatory challenges included navigating the regulatory guidelines and processes; confirming the eligibility of Local Technical Representatives (LTRs); and passing a joint inspection by Rwanda FDA/Uganda NDA to ensure compliance with Good Manufacturing Practices (GMP). Achieving registration was crucial for positioning BIOPHARMA as the first manufacturer to have its vaccine approved for eligibility in the AgResults Cost-Share Phase. 

Cost and Vaccine Accessibility Challenges:

1. Ensuring the FMD vaccine was affordable and accessible to disadvantaged communities in East Africa was a significant challenge. The project aimed to optimize production costs while ensuring the vaccine served as a cost-effective solution. The vaccine’s composition of five different strains added complexity to its production, necessitating cost reductions without compromising quality.
2. BIOPHARMA faced intense competition from well-established international vaccine producers with substantial resources. Competing with these global players required BIOPHARMA to remain innovative and efficient while maintaining high vaccine quality.

BIOPHARMA’s key challenges have been navigating the technical complexities of vaccine development, ensuring fast-tracked product registration, and making the vaccine affordable and competitive in a market dominated by larger producers. These obstacles have required leveraging expertise, adapting quickly, and working diligently to meet the project’s ambitious goals.

What does BIOPHARMA see at the biggest opportunity by participating in the AgResults project?

Participating in the AgResults project offers BIOPHARMA a significant opportunity to strengthen its position in the African market. The project aligns with BIOPHARMA’s strategic goals of expanding local production and offering vaccines tailored to the region’s epidemiological needs. Engaging in this initiative enhances BIOPHARMA’s presence in Africa and provides a platform to showcase its global capabilities. It demonstrates BIOPHARMA’s expertise in developing high-quality vaccines adapted to African challenges.

This opportunity builds BIOPHARMA’s reputation as a leading vaccine producer with a deep understanding of regional health issues, paving the way for future collaborations and market expansion.

Is there anything else you’d like to share about BIOPHARMA’s experience in the competition?

This project stands as a prime example of a successful strategic collaboration, driven by several key factors that contributed to its effectiveness and positive outcomes.

First, the project was built upon clear objectives that provided a strong foundation for all stakeholders involved. These well-defined goals ensured that each party understood its role and responsibilities, aligning efforts towards a common purpose. This clarity facilitated efficient decision-making and helped maintain focus on achieving measurable results.

Second, continuous communication and support played a crucial role in overcoming challenges and ensuring progress. Regular meetings and updates allowed all parties to address any constraints or issues as they arose, fostering a dynamic problem-solving environment. This consistent dialogue helped maintain momentum and ensured the project stayed on track, allowing for timely adjustments and improvements.

The project also benefited from a collaborative approach, bringing together experts from diverse fields, including technical specialists in FMD and marketing professionals. This multidisciplinary team developed a model integrating scientific expertise and market strategy, ensuring the vaccine’s development, distribution, and adoption maximized its impact and accessibility.

In conclusion, this project serves as a successful and replicable model for addressing other economically significant diseases in developing countries.

For more information about BIOPHARMA, visit their website. Learn more about BIOPHARMA’s participation in the AgResults FMD Vaccine Challenge Project here.

The AgResults Foot and Mouth Disease Vaccine Challenge Project is an eight-year, USD$17.34 million Pay-for-Results prize competition that supports the development, registration, and uptake of high-quality FMD vaccines that are tailored to meet the needs of Eastern Africa. Managed by GALVmed, the competition focuses on Burundi, Ethiopia, Kenya, Rwanda, Tanzania, and Uganda. The prize is structured as a cost-share that reduces the cost-per-dose for buyers, enabling public and private sector actors to better combat FMD through access to more effective vaccines. In this way, the project encourages the widespread use of prophylactic vaccination to improve animal health and farmer livelihoods. The competition launched in February 2020 and will conclude in July 2028.